Skip to main content
. 2013 Mar 4;110(12):4640–4645. doi: 10.1073/pnas.1213971110

Fig. 2.

Fig. 2.

BMP7 promotes SMAD-mediated signaling in nephron progenitors. (A) BMP7 treatment results in pSMAD1/5 (green) activation in PAX2 progenitors (red); costaining is yellow. (B) Immunofluorescence of E17.5 kidney sections shows nuclear pSMAD1/5 in the distal cap underneath collecting duct tips (arrows). Inset shows CITED1 (red) and pSMAD1/5 (green) at the CITED1+/CITED1− border. (C) CITED1 staining (red) of NZCs pretreated with vehicle, BMP7, BMP7 + dorsomorphin (DM), or BMP7 + TAK1 inhibitor (TAKi) shows that SMAD1/5 inhibition blocks the ability of BMP7 to reduce CITED1 expression. (D) Quantitative PCR analysis shows that inhibition of SMAD-dependent signaling by DM, compared with TAKi, blocks the ability of BMP7 to reduce transcription (48 h) of a group of early progenitor markers (Cited1, Meox1, Dpf3). Raw data are normalized to β-actin expression, and fold changes are relative to the vehicle control. (E) pSMAD1/5 in the distal cap mesenchyme is lost in the Bmp7−/−.